2026-05-17T01:18:29Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/259722025-12-18T12:56:24Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Garcia-Rubio, Rocio author Gonzalez-Jimenez, Irene author Lucio, Jose author Mellado, Emilia author 2021-03-01 Drug resistance poses a serious threat to human health and agricultural production. Azole drugs are the largest group of 14-α sterol demethylation inhibitor fungicides that are used both in agriculture and in clinical practice. As plant pathogenic molds share their natural environment with fungi that cause opportunistic infections in humans, both are exposed to a strong and persistent pressure of demethylase inhibitor (DMI) fungicides, including imidazole and triazole drugs. As a result, a loss of efficacy has occurred for this drug class in several species. In the clinical setting, azole resistance is a growing public health problem and finding the source of this resistance has gained much attention. It is urgent to determine if there is a direct link between the agricultural use of azole compounds and the different resistance mechanisms described for clinical triazoles. In this work we have performed susceptibility testing to clinical triazoles and crop protection DMIs using a collection of azole susceptible and resistant strains which harbor most of the described azole resistance mechanisms. Various DMI susceptibility profiles have been found in the different populations groups based on their azole resistance mechanism and previous WGS analysis, which suggests that the different resistance mechanisms have different origins and are specifically associated to the local use of a particular DMI. Importance: Due to the worldwide emergence of azole resistance, this opportunistic pathogen poses a serious health threat and, therefore, it has been included in the Watch List of the CDC 2019 Antimicrobial Resistance Threats Report. Azoles play a critical role in the control and management of fungal diseases, not only in the clinical setting but also in agriculture. Thus, azole resistance leads to a limited therapeutic arsenal which reduces the treatment options for aspergillosis patients, increasing their mortality risk. Evidence is needed to understand whether azole resistance is emerging from an agricultural source due to the extended use of demethylase inhibitors as fungicides, or whether it is coming from somewhere else such as the clinical setting. If the environmental route is demonstrated, the current use and management of azole antifungal compounds might be forced to change in the forthcoming years. Garcia-Rubio R, Gonzalez-Jimenez I, Lucio J, Mellado E. Characterization of Aspergillus fumigatus cross-resistance between clinical and DMI azole drugs. Appl Environ Microbiol. 2021 Mar 1;87(5):e02539-20. 10.1128/AEM.02539-20 1098-5336 0099-2240 Applied and environmental microbiology https://pmc.ncbi.nlm.nih.gov/articles/PMC8090891/ 33355104 https://hdl.handle.net/20.500.12105/25972 Characterization of Aspergillus fumigatus cross-resistance between clinical and DMI azole drugs